CP
AGIO icon

Caligan Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Caligan Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,131,205
Closed -$39.7M – 25
2025
Q3 		$45.4M Buy
1,131,205
+59,947
+6% +$2.25M 5.95% 6
2025
Q2 		$35.6M Buy
1,071,258
+369,978
+53% +$11.2M 6.85% 4
2025
Q1 		$20.5M Buy
701,280
+75,000
+12% +$2.49M 4.29% 9
2024
Q4 		$20.6M Buy
626,280
+46,563
+8% +$2.19M 5.21% 7
2024
Q3 		$25.8M Buy
579,717
+65,006
+13% +$2.95M 8.16% 6
2024
Q2 		$22.2M Buy
514,711
+30,000
+6% +$1.08M 5.19% 8
2024
Q1 		$14.2M Buy
484,711
+42,878
+10% +$1.15M 3.75% 8
2023
Q4 		$9.84M Buy
441,833
+437,000
+9,042% +$9.79M 3.32% 7
2023
Q3 		$120K Hold
4,833
– – 0.05% 13
2023
Q2 		$137K Buy
4,833
+500
+12% +$12.4K 0.08% 13
2023
Q1 		$99.5K Hold
4,333
– – 0.07% 11
2022
Q4 		$122K Buy
+4,333
New +$122K 0.1% 11

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Caligan Partners's AGIO Position: Q4 2025 in Review

Caligan Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 1,131,205 shares — an estimated $39.7M sold.

Caligan Partners first reported a position in AGIO in Q4 2022 and held it in 12 quarters. The position peaked at $45.4M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Caligan Partners reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Caligan Partners sold 1,131,205 Agios Pharmaceuticals shares in Q4 2025, an estimated $39.7M.
  • Caligan Partners first reported a position in Agios Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Caligan Partners's Agios Pharmaceuticals position peaked at $45.4M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Caligan Partners's 13F filing for Q4 2025, filed 17 Feb 2026.